Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
0.9185 USD -1.46% Intraday chart for Lineage Cell Therapeutics, Inc. +2.06% -15.73%
Jul. 02 Lineage Cell Therapeutics Included in Russell 3000 Index MT
May. 21 Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
LINEAGE CELL THERAPEUTICS ADDED TO MEMBERSHIP OF 2024 RUSSELL 3000 INDEX
AQ
Lineage Cell Therapeutics Included in Russell 3000 Index
MT
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
BU
Lineage Cell Therapeutics : Changes in Registrant’s Certifying Accountant
PU
Lineage Cell Therapeutics : Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holder
PU
Lineage to Present at 2024 BIO International Convention
BU
Lineage Cell Therapeutics : FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP CULLEY BRAIN M
PU
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
BU
Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
CI
Lineage Cell Therapeutics : Opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares
PU
Lineage Cell Therapeutics : Prospectus disclosing information, facts, events
PU
Lineage Cell Therapeutics : Immediate Report
PU
Lineage Cell: Q1 Earnings Snapshot
AQ
Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M
MT
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
BU
LINEAGE CELL - OPREGEN PHASE 1/2A CLINICAL STUDY 24-MONTH VISUAL ACUITY RESULTS FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT
AQ
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
BU
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LCTX Stock
  4. News Lineage Cell Therapeutics, Inc.